IL33 and melanoma: Overall, our studies underscore an important role for IL-33/ST2 in driving tumor-immune cross talk and indicate DAC as a positive regulator of this axis that can further increase anti-tumor effects of IL-33 in combinatorial approaches against melanoma, including the use of ICB.